A case of long-term disease control in a patient with disseminated melanoma with synchronous detection of multiple brain metastases
https://doi.org/10.17709/2409-2231-2018-5-4-10
Abstract
The article presents clinical trials data of melanoma with brain metastasis and a clinical case of long-term survival of a patient with disseminated skin melanoma and synchronous multiple metastatic brain damage by controlling a tumor disease using modern antitumor treatment, including targeted therapy, immunotherapy, radiation therapy, radiosurgery and neurosurgery (at the stage of diagnosis). The total duration of life after detection of the disease is 22 months, with an expected 2-3 months.
About the Author
M. I. Kurzhupov
Clinical Diagnostic Center No. 4 of the Moscow Healthcare Department; Russian Scientific Center of Roentgenoradiology
Russian Federation
Competing Interests:
Russian Federation
Mikhail I. Kurzhupov - MD, PhD, head of Oncology Department, CDC No. 4 of the Moscow Healthcare Department, neurosurgeonRSCR.
3 Krylatskie kholmy str., Moscow 121609
Competing Interests:
No conflict of interest
References
1. Korshunov A. G. Klassifikatsiya opukholei nervnoi sistemy. Klinicheskaya nevrologiya [Classification of tumors of the nervous system. Clinical neurology]. Edited by A. N. Konovalov. Vol. III. Мoscow, 2014, 171 pp. (In Russian).
2. Larson D, Rubenstein JM, McDermott, Asbell S, Phillips T, Was-serman T, et al. Treatment of Metastatic Cancer: Cancer Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins, 2004. 2323-2398 pp.
3. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997 Mar 1;37 (4):745-51. DOI: 10.1016/j.ctrv.2004.05.001
4. Kaprin AD, Starinskii VV, Petrova VV. State of cancer care to the population of Russia in 2016. Мoscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, 2017, 266 p. (In Russian).
5. Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev. 2004 Oct;30 (6):515-20.
6. Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control. 2009 Jul;16 (3):248-55. DOI: 10.1177/107327480901600307
7. Akimov M. A., Gershanovich M. L. Klinicheskaya otsenka ef-fektivnosti sovremennykh rezhimov khimioterapii pervoi, vto-roi i tret'ei linii u bol'nykh disseminirovannoi melanomy kozhi. Voprosy oncologii (Problems in Oncology). 2001;47 (4):428-35. (In Russian).
8. Gonzalez-Martinez J, Hernandez L, Zamorano L, Sloan A, Levin K, Lo S, Li Q, Diaz F. Gamma knife radiosurgery for intracranial metastatic melanoma: a 6-year experience. J Neurosurg. 2002 Dec;97 (5 Suppl):494-8.
9. National Comprehensive Cancer Network. Central nervous system cancers. NCCN Guidelines. Version 1.2013. 2012.
10. Naskhletashvili DR, Banov SM, Bekyashev AK, et al. Practical guiedlines of systemic treatment of cancer brain me-tastases. Malignant Tumoursis. 2017;7 (S2):93-104. DOI: 10.18027/2224-5057-2017-7-3s2-93-l04
11. Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAFV600-mu-tant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017 Jul;18 (7):863-873. DOI: 10.1016/S1470-2045(17)30429-1
12. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov;13 (11):1087-95. DOI: 10.1016/S1470-2045(12)70431-X.
13. Goldberg SB, Geffinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016 Jul;17 (7):976-983. DOI: 10.1016/S1470-2045(16)30053-5.
14. Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 May;19 (5):672-681. DOI: 10.1016/S1470-2045(18)30139-6
15. Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Aug 23;379 (8):722-730. DOI: 10.1056/NEJMoa1805453.
16. Weber J, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016 Jul;17 (7):943-955. DOI: 10.1016/ S1470-2045(16)30126-7
Review
For citations:
Kurzhupov M.I. A case of long-term disease control in a patient with disseminated melanoma with synchronous detection of multiple brain metastases. Research and Practical Medicine Journal. 2018;5(4):98-105. (In Russ.) https://doi.org/10.17709/2409-2231-2018-5-4-10
Views:
937
Email this article 